https://www.selleckchem.com/pr....oducts/enfortumab-ve
13 months) but with no significant difference after PSM (16 months vs. 17 months). The high-risk factors for the development of cervical cancer to CC-NSCLC include age 50-79 years, black race [odds ratio (OR) 1.417; 95% confidence interval (CI) 1.095-1.834; P 0.05], and history of radiotherapy (OR 1.392; 95% CI 1.053-1.841; P 0.05). Age 50-79 years, black race, and history of radiotherapy were independent risk factors for second primary lung cancer in patients with cervical cancer. Patients with CC-NSCLC had di
Like
Comment
Share
